Urological Research

, Volume 22, Issue 6, pp 353–360 | Cite as

Establishment and characterization of a multidrug-resistant human bladder carcinoma cell line RT112/D21

  • O. Seemann
  • M. Muscheck
  • M. Siegsmund
  • H. Pilch
  • C. T. Nebe
  • J. Rassweiler
  • P. Alken
Original Paper


A doxorubicin-resistant human bladder carcinoma cell line RT112/D21 was established by continuous exposure of the parental line RT112 to increasing concentrations of doxorubicin over a period of 9 months. RT112/D21 cells expressed significantly more P-170 glycoprotein than the parental line, and rhodamine 123 efflux, as a functional parameter of P-170 glycoprotein activity, was increased. RT112/D21 cells were 96 times more resistant to doxorubicin than RT112 cells, and crossresistance to epirubicin and vinblastine was present. Sensitivity to methotrexate and mitomycin C remained unchanged. R-verapamil reversed resistance to doxorubicin, epirubicin and vinblastine in RT112/D21 cells but did not affect sensitivity to methotrexate and mitomycin C. In RT112 cells, R-verapamil had no effect on drug sensitivity. Thus, it may be assumed that primary or induced MDR1 gene-encoded P-170 glycoprotein expression is a relevant mechanism of chemoresistance in transitional cell carcinoma, and that chemotherapeutic strategies in combination with chemosensitizers improve response rates.

Key words

Bladder cancer Doxorubicin Multidrug resistance P-170 glycoprotein Rhodamine 123 R-verapamil 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Alley M, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR (1988) Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48:589Google Scholar
  2. 2.
    Benson MC, Gielia J, Seong Whang I, Buttyan R, Hensle TW, Karp F, Olson CA (1991) Flow cytometric determination of the multidrug resistant phenotype in transitional cell cancer of the bladder: Implications and applications. J Urol 146:983Google Scholar
  3. 3.
    Bissett D, Kerr DJ, Cassidy J, Meredith P, Traugott U, Kaye SB (1991) Phase I and pharmacokinetic study of d-verapamil and doxorubicin. Br J Cancer 64:1168Google Scholar
  4. 4.
    Cole SPC, Downes HF, Slovak ML (1989) Effect of calcium antagonists on the chemosensitivity of two multidrug resistant human tumor cell lines which do not overexpress P-glycoprotein. Br J Cancer 59:42Google Scholar
  5. 5.
    Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV, Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650Google Scholar
  6. 6.
    Echizen H, Brecht T, Niedergäss S, Vogelgesang B, Eichbaum M (1985) The effect of dextro-, levo-, and racemic verapamil on atrioventricular conduction in humans. Am Heart J 109:210Google Scholar
  7. 7.
    Efferth T, Löhrke H, Volm M (1989) Reciprocal correlation between expression of P-glycoprotein and accumulation of rhodamine 123 in human tumors. Anticancer Res 9:1633Google Scholar
  8. 8.
    FitzGerald DJ, Willingham MC, Cardarelli CO, Hamada H, Tsuruo T, Gottesmann MM, pastan I (1987) A monoclonal antibody-pseudomonas toxin conjugate that specifically kills multidrug-resistant cells. Proc Natl Acad Sci 84:4288Google Scholar
  9. 9.
    Floyd JW, Lin C-W, Prout GR Jr (1990) Multi-drug resistance of a doxorubicin-resistant bladder cancer cell line. J Urol 144:169Google Scholar
  10. 10.
    Ford JM, Hait W (1990) Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42:155Google Scholar
  11. 11.
    Gerlach JH, Endicott JA, Juranka PF, Henderson G, Sarangi F, Deuchars KL, Ling V (1986) Homology between P-glycoprotein and a bacterial haemolysin transport protein suggest a model for multidrug resistance. Nature 324:485Google Scholar
  12. 12.
    Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SPC, Deeley RG (1994) Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 54:357Google Scholar
  13. 13.
    Grogan T, Dalton W, Rybski J, Spier C, Meltzer P, Richter L, Greason M, Pindur J, Cline A, Scheper R, Tsuruo T, Salmon S (1990) Optimization of immunocytochemical P-glycoprotein assessment in multidrug-resistant plasma cell myeloma using three antibodies. Lab Invest 63:815Google Scholar
  14. 14.
    Gruber A, Peterson C, Reizenstein P (1988) d-verapamil and l-verapamil are equally effective in increasing vincristine accumulation in leukemic cells in vitro. Int J Cancer 41:224Google Scholar
  15. 15.
    Harris AL, Hochhauser D (1992) Mechanisms of multidrug resistance in cancer treatment. Acta Oncol 31:205Google Scholar
  16. 16.
    Herr HW, Laudone VP, Whitmore JWF (1987) An overview of intravesical therapy for superficial bladder tumors. J Urol 138:1362Google Scholar
  17. 17.
    Herweijler H, Engh G, Nooter K (1989) A rapid and sensitive flow cytometric method for the detection of multidrug-resistant cells. Cytometry 10:463Google Scholar
  18. 18.
    Hill BT, van der Graaf WT, Hoskin LK, de Vries EG, Mulder NH, Whelan RD (1993) Evaluation of S9788 as a potential modulator of drug resistance against human tumour sublines expressing different resistance mechanisms in vitro. Int J Cancer 55:330Google Scholar
  19. 19.
    Kartner N, Evernden-Porelle D, Bradley G, Ling V (1985) Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 316:820Google Scholar
  20. 20.
    Kimiya K, Naito S, Soejiraa T, Sakamoto N, Kotoh S, Kumazawa J, Tsuruo T (1992) Establishment and characterization of doxorubicin-resistant human bladder cancer cell line, KK47/ADM. J Urol 148:441Google Scholar
  21. 21.
    Kruh GD, Chan A, Myers K, Gaughan K, Miki T, Aaronson SA (1994) Expression of complementary DNA library transfer establishes mrp as a multidrug resistance gene. Cancer Res 54:649Google Scholar
  22. 22.
    Lin Wu, Smythe AM, Sherman FS, Mullendore LA, Monks A, Scudiero DA, Paull KD, Koutsoukos AD, Rubinstein LV, Boyd MR, Shoemaker RH (1992) Multidrug-resistant phenotype of disease-orientated panels of human tumor cell lines used for anticancer drug screening. Cancer Res 52:3029Google Scholar
  23. 23.
    Ludescher C, Thaler J, Drach D, Drach J, Spitaler M (1992) Detection of activity of P-glycoprotein in human tumour samples using rhodamine 123. Br J Haematol 82:161Google Scholar
  24. 24.
    Lukkarinen O, Paul C, Hellstrom P, Kontturi M, Nurmi M, Puntala P, Ottelin J, Tammeala T, Tidefeldt U (1991) Intravesical epirubicin with and without verapamil for the prophylaxis of superficial bladder tumours. Scand J Urol Nephrol 25(1):25Google Scholar
  25. 25.
    McGovern F, Kachel T, Vijan S, Schiff S, Lin C, Prout GR Jr (1988) Establishment and characterization of a doxorubicinresistant human bladder cancer cell line (MGH-U1R). J Urol 140:410Google Scholar
  26. 26.
    Mickisch G, Bier H, Bergler M, Bak M, Tschada R, Alken P (1990) P-170 glycoprotein, glutathione and associated enzymes in relation to chemoresistance of primary human renal cell carcinomas. Urol Int 45:170Google Scholar
  27. 27.
    Mickisch GH, Roehrich K, Koessig J, Forster S, Tschada R, Alken P (1990) Mechanisms and modulation of multidrug resistance in primary human renal cell carcinoma. J Urol 144:755Google Scholar
  28. 28.
    Mirski SEL, Gerlach JH, Cole SPC (1987) Multidrug resistance in human small cell cancer cell line selected in adriamycin. Cancer Res 47:2594Google Scholar
  29. 29.
    Moriyama M, Sugawara I, Hamada H, Tsuruo T, Kato T, Sato K, Hikage T, Watanuki T, Mori S (1991) Elevated expression of P-glycoprotein in kidney and urinary bladder cancers. Tohoku J Exp Med 164:191Google Scholar
  30. 30.
    Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. J Immunol Methods 65:55Google Scholar
  31. 31.
    Naito S, Sakamoto N, Katoh S, Goto K, Matsumoto T, Kumazawa J (1992) Correlation between the expression of P-glycoprotein and the multidrug-resistant phenotype in transitional cell carcinoma of the urinary tract. Eur Urol 22:158Google Scholar
  32. 32.
    Nakagawa M, Schneider E, Dixon KH, Horton J, Keley K, Morrow C, Cowan KH (1992) Reduced intracellular drug accumulation in absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells. Cancer Res 52:6175Google Scholar
  33. 33.
    Nooter K, Herrweijer H (1991) Multidrug resistance (mdr) genes in human cancer. Br J Cancer 63:663Google Scholar
  34. 34.
    Ohi Y, Ohmori H, Shirahama T, Kawahara M, Matsumara Y, Tsushima T, Ohashi Y (1992) Intravesical instillation of adriamycin in the presence or absence of verapamil for the treatment of superficial bladder cancer: preliminary report of a collaborative study. Cancer Chemother Pharmacol 30[Suppl]:50Google Scholar
  35. 35.
    Raghu G, Pierre-Jerome M, Dordal MS, Simonian P, Bauer KD, Winter JN (1993) P-glycoprotein and alterations in the glutathione/glutathione-peroxidase cycle underlie doxorubicin resistance in HL-60-R, a subclone of the HL-60 human leukemia cell line. Int J Cancer 53:804Google Scholar
  36. 36.
    Rassweiler J, Hath U, Bub P, Eisenberger F (1988) Intravesicale Langzeitchemoprophylaxe mit Mitomycin C beim oberflächlichen Harnblasenkarzinom — Rezidivverhalten und Progression nach 3 Jahren. Aktuelle Urol 19:139Google Scholar
  37. 37.
    Remmele W, Stegner HE (1986) Rezeptorbestimmung im Mammakarzinomgewebe. Dtsch Ärzteblatt 83:11Google Scholar
  38. 38.
    Rivoltini L, Colombo MP, Supino R, Dallinari D, Tsuruo T, Parmiani G (1990) Modulation of multidrug resistance by verapamil or mdr1 anti-sense oligodesoxynucleotide does not change the high susceptibility to lymphokine-activated killers in mdr resistant human carcinoma (LoVo)line. Int J Cancer 46:727Google Scholar
  39. 39.
    Sekine H, Fukui I, Yamada T, Ohwada F, Yokokawa M, Ohshima H (1994) Intravesical mitomycin C sequential therapy for carcinoma in situ of the bladder: a longer followup result. J Urol 151:27Google Scholar
  40. 40.
    Simpson WG, Tseng MT, Anderson KC, Harty JJ (1984) Verapamil enhancement of chemotherapeutic efficacy in human bladder cancer cells. J Urol 132:574Google Scholar
  41. 41.
    Sternberg CN, Yagoda A, Scher HI, Watson RC, Herr HW, Morse MJ, Sogani PC, Vaughan D Jr, Bander N, Weiselberg LR, Geller N, Hollander PS, Lipperman R, Fair WS, Whitmore WF Jr (1988) M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 139:461Google Scholar
  42. 42.
    Suzukake K, Vistica BP, Vistica DT (1983) Dechlorination of l-phenylalanine mustard by sensitive and resistant tumor cells and its relationship to intracellular glutathione content. Biochem Pharmacol 32:165Google Scholar
  43. 43.
    Tsuruo T, Indan H, Tsukagoshi S, Sukarai Y (1991) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41:1967Google Scholar

Copyright information

© Springer-Verlag 1995

Authors and Affiliations

  • O. Seemann
    • 1
  • M. Muscheck
    • 2
  • M. Siegsmund
    • 2
  • H. Pilch
    • 3
  • C. T. Nebe
    • 4
  • J. Rassweiler
    • 2
  • P. Alken
    • 2
  1. 1.Klink für Urologie, Städtisches Krankenhaus HeilbronnAkademisches Lehrkrankenhaus der Universität HeidelbergHeilbronnGermany
  2. 2.Department of Urology, Faculty of Clinical Medicine, Mannheim Hospital, School of MedicineUniversity of HeidelbergMannheimGermany
  3. 3.Department of Pathology, Faculty of Clinical Medicine, Mannheim Hospital, School of MedicineUniversity of HeidelbergMannheimGermany
  4. 4.Department of Clinical Chemistry, Faculty of Clinical Medicine, Mannheim Hospital, School of MedicineUniversity of HeidelbergMannheimGermany

Personalised recommendations